Observational studyEuropean journal of medical research2025
Real-world application of surufatinib in the treatment of neuroendocrine tumors: a multi-center retrospective study in China.
Observational study in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Recently, the incidence of neuroendocrine tumors (NETs), characterized by neuroendocrine differentiation, has increased. Their heterogeneous origins and biological behaviors complicate diagnosis and treatment. Surufatinib, a novel oral tyrosine kinase inhibitor with dual anti-angiogenic and immunomodulatory properties, has shown promising efficacy against NETs in recent clinical trials. However, comparative data on the prognostic impact of surufatinib treatment remain limited. We investigated risk factors associated with mortality and tumor progression in patients with NETs, and aimed to provide insights into the administration of surufatinib to improve the clinical outcomes of these patients. In this multi-center, observational study, we retrospectively analyzed 373 patients diagnosed with NETs and followed up for 1 year. All patients received anti-tumor treatments during their hospitalization, including chemotherapy, radiotherapy, surgery, and immunosuppressants. Among them, 93 patients received surufatinib. Logistic regression was performed to identify potential risk factors, which were subsequently adjusted for confounding variables using a Cox proportional hazards regression model. Multivariable analysis revealed that surufatinib use was an independent risk factor for death (OR 0.36, P = 0.006) and disease progression (OR 0.44, P = 0.005). Survival analysis showed significantly higher overall (HR 0.44, 95% CI 0.26-0.76, P = 0.003) and progression-free survival (HR 0.56, 95% CI 0.37-0.84, P = 0.005) among patients treated with surufatinib than those in patients not receiving treatment. A higher proportion of patients in the surufatinib treatment cohort experienced proteinuria (9 [3.2%] vs. 10 [10.8%], P = 0.010) and increased blood bilirubin levels (25 [8.9%] vs. 16 [17.2%], P = 0.027), however, no significant differences were observed in the severity of adverse reactions. Surufatinib showed clinically meaningful efficacy in patients with NETs and exhibited a generally manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.